MBRX (Moleculin Biotech) Cyclically Adjusted Book per Share: $1,269.02 (As of Mar. 2026)


MBRX Moleculin Biotech Inc MBRX
30 GF Score
Price $3.26
! 1 Warning Sign
View Full Analysis

What is Moleculin Biotech Cyclically Adjusted Book per Share?

Moleculin Biotech MBRX +9.00% 30 Cyclically Adjusted Book per Share is $1,269.02 as of Mar. 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Moleculin Biotech's adjusted book value per share for the three months ended in Mar. 2026 was $2.845. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1,269.02 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-06-28), Moleculin Biotech's current stock price is $3.26. Moleculin Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $1,269.02. Moleculin Biotech's Cyclically Adjusted PB Ratio of today is 0.00.


Moleculin Biotech  (NAS:MBRX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Moleculin Biotech's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.26/1269.02
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Moleculin Biotech Cyclically Adjusted Book per Share Related Terms


Moleculin Biotech Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Moleculin Biotech's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech Cyclically Adjusted Book per Share Chart

Moleculin Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1,241.38

Moleculin Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 1,239.86 1,241.38 1,269.02

MBRX vs ICU, LEXX, INTI: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Moleculin Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moleculin Biotech Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moleculin Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Moleculin Biotech's Cyclically Adjusted PB Ratio falls into.


MBRX
30GF Score
Moleculin Biotech Inc MBRX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moleculin Biotech Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Moleculin Biotech's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.845/330.2130*330.2130
=2.845

Current CPI (Mar. 2026) = 330.2130.

Moleculin Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201606 3,446.200 241.018 4,721.556
201609 3,248.800 241.428 4,443.544
201612 2,992.000 241.432 4,092.238
201703 2,017.750 243.801 2,732.914
201706 2,141.000 244.955 2,886.187
201709 2,072.333 246.819 2,772.523
201712 1,711.800 246.524 2,292.915
201803 1,870.000 249.554 2,474.408
201806 1,395.667 251.989 1,828.919
201809 1,247.333 252.439 1,631.624
201812 1,097.846 251.233 1,442.975
201903 978.800 254.202 1,271.479
201906 1,104.600 256.143 1,424.022
201909 948.750 256.759 1,220.170
201912 778.550 256.974 1,000.441
202003 637.167 258.115 815.144
202006 578.852 257.797 741.453
202009 535.815 260.280 679.780
202012 572.903 260.474 726.291
202103 1,164.684 264.877 1,451.971
202106 1,114.474 271.696 1,354.506
202109 1,069.197 274.310 1,287.094
202112 1,039.382 278.802 1,231.044
202203 956.118 287.504 1,098.150
202206 873.145 296.311 973.045
202209 768.645 296.808 855.154
202212 686.724 296.797 764.041
202303 578.278 301.836 632.645
202306 509.722 305.109 551.661
202309 444.785 307.789 477.190
202312 292.955 306.746 315.367
202403 234.641 312.332 248.074
202406 173.578 314.175 182.439
202409 62.325 315.301 65.273
202412 83.022 315.605 86.865
202503 0.074 319.799 0.076
202506 -5.931 322.561 -6.072
202509 -13.596 324.800 -13.823
202512 4.691 324.054 4.780
202603 2.845 330.213 2.845

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $1,269.02 mean?
Moleculin Biotech (MBRX) has a Cyclically Adjusted Book per Share of $1,269.02 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Moleculin Biotech and its competitors.
Is Moleculin Biotech's Cyclically Adjusted Book per Share too high?
Moleculin Biotech's current Cyclically Adjusted Book per Share is $1,269.02. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's Cyclically Adjusted Book per Share compare to ICU and LEXX?
Moleculin Biotech's Cyclically Adjusted Book per Share of $1,269.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Moleculin Biotech and its competitors. Moleculin Biotech's current Cyclically Adjusted Book per Share is $1,269.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current Cyclically Adjusted Book per Share of $1,269.02. The current Cyclically Adjusted Book per Share is $1,269.02. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current Cyclically Adjusted Book per Share is $1,269.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moleculin Biotech Business Description

Other Exchanges 0K2H:UK
Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score

Get the complete analysis for MBRX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.26
Price